Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 48 | 2025 | 845 | 12.840 |
Why?
|
| Kidney Failure, Chronic | 45 | 2025 | 868 | 11.440 |
Why?
|
| Peritoneal Dialysis | 9 | 2023 | 118 | 5.540 |
Why?
|
| Medicare | 17 | 2023 | 422 | 3.540 |
Why?
|
| Prospective Payment System | 5 | 2021 | 16 | 2.420 |
Why?
|
| United States | 42 | 2023 | 10740 | 2.010 |
Why?
|
| Ambulatory Care | 5 | 2021 | 378 | 1.980 |
Why?
|
| Hemodialysis, Home | 4 | 2022 | 13 | 1.960 |
Why?
|
| Economic Competition | 4 | 2023 | 14 | 1.760 |
Why?
|
| Nephrologists | 3 | 2021 | 13 | 1.550 |
Why?
|
| Ambulatory Care Facilities | 6 | 2021 | 229 | 1.540 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 605 | 1.480 |
Why?
|
| Health Facility Closure | 2 | 2021 | 8 | 1.450 |
Why?
|
| Health Care Sector | 3 | 2020 | 19 | 1.420 |
Why?
|
| Renal Insufficiency | 3 | 2023 | 234 | 1.420 |
Why?
|
| Health Policy | 4 | 2020 | 213 | 1.410 |
Why?
|
| Patient Readmission | 4 | 2017 | 375 | 1.270 |
Why?
|
| Reimbursement Mechanisms | 4 | 2023 | 38 | 1.210 |
Why?
|
| Cost-Benefit Analysis | 5 | 2025 | 505 | 1.190 |
Why?
|
| Hematinics | 2 | 2023 | 57 | 1.180 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 722 | 1.100 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2024 | 96 | 1.090 |
Why?
|
| Fee-for-Service Plans | 2 | 2016 | 18 | 1.070 |
Why?
|
| Nephrology | 3 | 2019 | 144 | 1.070 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 478 | 1.060 |
Why?
|
| Medicaid | 6 | 2019 | 243 | 1.040 |
Why?
|
| Health Expenditures | 4 | 2022 | 103 | 0.980 |
Why?
|
| Hemodiafiltration | 1 | 2025 | 18 | 0.970 |
Why?
|
| Financing, Government | 2 | 2023 | 30 | 0.960 |
Why?
|
| Humans | 65 | 2025 | 124092 | 0.940 |
Why?
|
| Health Care Costs | 4 | 2025 | 369 | 0.940 |
Why?
|
| Anemia | 2 | 2023 | 341 | 0.930 |
Why?
|
| Aged | 26 | 2024 | 19352 | 0.920 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2014 | 16 | 0.890 |
Why?
|
| Hospitalization | 4 | 2021 | 1751 | 0.880 |
Why?
|
| Benzazepines | 2 | 2014 | 64 | 0.870 |
Why?
|
| Vitamin D | 2 | 2018 | 159 | 0.860 |
Why?
|
| Registries | 8 | 2022 | 1407 | 0.840 |
Why?
|
| National Health Programs | 1 | 2023 | 19 | 0.840 |
Why?
|
| Accountable Care Organizations | 1 | 2020 | 7 | 0.720 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2020 | 717 | 0.700 |
Why?
|
| Insurance, Health | 2 | 2018 | 137 | 0.690 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2020 | 9 | 0.690 |
Why?
|
| Health Facility Merger | 2 | 2019 | 10 | 0.690 |
Why?
|
| Middle Aged | 24 | 2024 | 26320 | 0.670 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 721 | 0.650 |
Why?
|
| Reimbursement, Incentive | 2 | 2023 | 47 | 0.650 |
Why?
|
| Safety-net Providers | 1 | 2019 | 49 | 0.640 |
Why?
|
| Specialization | 1 | 2019 | 76 | 0.630 |
Why?
|
| Models, Organizational | 1 | 2019 | 40 | 0.630 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 634 | 0.630 |
Why?
|
| Nurse Practitioners | 1 | 2019 | 44 | 0.620 |
Why?
|
| Male | 34 | 2024 | 60815 | 0.620 |
Why?
|
| Physician Assistants | 1 | 2019 | 64 | 0.600 |
Why?
|
| Commerce | 1 | 2018 | 52 | 0.590 |
Why?
|
| Female | 34 | 2024 | 66165 | 0.580 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 117 | 0.570 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 123 | 0.570 |
Why?
|
| Physicians | 2 | 2023 | 583 | 0.550 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 1886 | 0.550 |
Why?
|
| Telemedicine | 1 | 2023 | 433 | 0.550 |
Why?
|
| Insurance Coverage | 1 | 2017 | 121 | 0.530 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 209 | 0.530 |
Why?
|
| Hemoglobins | 2 | 2023 | 303 | 0.520 |
Why?
|
| Mobility Limitation | 1 | 2015 | 25 | 0.500 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 5 | 0.490 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 428 | 0.470 |
Why?
|
| Vascular Access Devices | 1 | 2014 | 35 | 0.470 |
Why?
|
| Office Visits | 1 | 2015 | 77 | 0.460 |
Why?
|
| Health Resources | 1 | 2015 | 115 | 0.440 |
Why?
|
| Pravastatin | 1 | 2013 | 23 | 0.430 |
Why?
|
| Cohort Studies | 8 | 2019 | 4728 | 0.420 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 484 | 0.420 |
Why?
|
| Rhabdomyolysis | 1 | 2013 | 36 | 0.410 |
Why?
|
| Health Care Reform | 3 | 2020 | 50 | 0.410 |
Why?
|
| Hyperparathyroidism | 1 | 2010 | 24 | 0.360 |
Why?
|
| Naphthalenes | 1 | 2010 | 37 | 0.360 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 458 | 0.360 |
Why?
|
| Residence Characteristics | 1 | 2013 | 271 | 0.360 |
Why?
|
| Ownership | 3 | 2019 | 31 | 0.340 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 1415 | 0.340 |
Why?
|
| Retrospective Studies | 10 | 2024 | 16197 | 0.310 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 595 | 0.310 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 170 | 0.300 |
Why?
|
| Adult | 12 | 2024 | 29307 | 0.300 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2013 | 106 | 0.290 |
Why?
|
| Cost Savings | 2 | 2020 | 72 | 0.290 |
Why?
|
| Time Factors | 7 | 2019 | 6256 | 0.280 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1084 | 0.280 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 853 | 0.280 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 800 | 0.270 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12240 | 0.250 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 1010 | 0.250 |
Why?
|
| Stroke | 1 | 2013 | 970 | 0.240 |
Why?
|
| Forearm | 1 | 2024 | 44 | 0.230 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3406 | 0.230 |
Why?
|
| Ferritins | 1 | 2023 | 96 | 0.210 |
Why?
|
| Markov Chains | 2 | 2013 | 83 | 0.210 |
Why?
|
| Disease Progression | 3 | 2013 | 2037 | 0.200 |
Why?
|
| Travel | 1 | 2023 | 116 | 0.200 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 93 | 0.200 |
Why?
|
| Patient Care Bundles | 1 | 2021 | 23 | 0.190 |
Why?
|
| Iron | 1 | 2023 | 267 | 0.180 |
Why?
|
| Neoplasms | 1 | 2015 | 2782 | 0.180 |
Why?
|
| Propensity Score | 1 | 2021 | 212 | 0.180 |
Why?
|
| China | 1 | 2021 | 242 | 0.180 |
Why?
|
| Health Facilities, Proprietary | 1 | 2019 | 3 | 0.170 |
Why?
|
| Data Collection | 1 | 2022 | 384 | 0.170 |
Why?
|
| Benzofurans | 1 | 2019 | 24 | 0.170 |
Why?
|
| Quinoxalines | 1 | 2019 | 40 | 0.170 |
Why?
|
| Logistic Models | 2 | 2016 | 1805 | 0.170 |
Why?
|
| Medically Uninsured | 1 | 2019 | 73 | 0.160 |
Why?
|
| Patient Care | 1 | 2020 | 100 | 0.160 |
Why?
|
| Decision Support Techniques | 2 | 2013 | 280 | 0.160 |
Why?
|
| Ezetimibe | 1 | 2019 | 95 | 0.160 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 54 | 0.160 |
Why?
|
| Outpatients | 1 | 2020 | 254 | 0.150 |
Why?
|
| Indians, North American | 1 | 2018 | 59 | 0.150 |
Why?
|
| Imidazoles | 1 | 2019 | 194 | 0.150 |
Why?
|
| Risk Factors | 4 | 2018 | 10110 | 0.150 |
Why?
|
| Central Venous Catheters | 1 | 2018 | 39 | 0.150 |
Why?
|
| Policy Making | 1 | 2018 | 59 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 604 | 0.150 |
Why?
|
| Employment | 1 | 2018 | 67 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2018 | 285 | 0.140 |
Why?
|
| Program Development | 1 | 2018 | 187 | 0.140 |
Why?
|
| Physician's Role | 1 | 2019 | 165 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2023 | 771 | 0.140 |
Why?
|
| Hospitals | 1 | 2019 | 395 | 0.140 |
Why?
|
| Cause of Death | 1 | 2018 | 466 | 0.130 |
Why?
|
| Graft Survival | 1 | 2018 | 530 | 0.130 |
Why?
|
| Kidney | 4 | 2024 | 1344 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2018 | 448 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2016 | 279 | 0.130 |
Why?
|
| Heart Transplantation | 1 | 2022 | 858 | 0.130 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 324 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 1180 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2019 | 546 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2019 | 746 | 0.120 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 143 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2020 | 638 | 0.110 |
Why?
|
| Risk | 2 | 2013 | 748 | 0.110 |
Why?
|
| Public Health | 1 | 2016 | 260 | 0.110 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1045 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2013 | 53 | 0.110 |
Why?
|
| Young Adult | 4 | 2019 | 8939 | 0.110 |
Why?
|
| Drug Costs | 1 | 2013 | 60 | 0.100 |
Why?
|
| Hypertension, Renal | 1 | 2012 | 37 | 0.100 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 177 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 1153 | 0.100 |
Why?
|
| Heparin | 1 | 2014 | 227 | 0.100 |
Why?
|
| Proteinuria | 1 | 2012 | 110 | 0.100 |
Why?
|
| Age of Onset | 1 | 2013 | 583 | 0.100 |
Why?
|
| Morbidity | 1 | 2012 | 243 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2013 | 166 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2016 | 477 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1306 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 376 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1694 | 0.090 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2015 | 535 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2014 | 458 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2016 | 519 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2014 | 493 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 1012 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2013 | 1245 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2156 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 6436 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1266 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 428 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2014 | 581 | 0.080 |
Why?
|
| Hypertension | 1 | 2013 | 1286 | 0.060 |
Why?
|
| Arm | 1 | 2024 | 78 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5087 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 2411 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 315 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2023 | 531 | 0.040 |
Why?
|
| Carbamates | 1 | 2019 | 61 | 0.040 |
Why?
|
| Amides | 1 | 2019 | 83 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2019 | 68 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 133 | 0.040 |
Why?
|
| Unemployment | 1 | 2018 | 20 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2019 | 241 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2019 | 262 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2018 | 213 | 0.030 |
Why?
|
| Adolescent | 3 | 2019 | 19272 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 133 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2016 | 131 | 0.030 |
Why?
|
| Patient Preference | 1 | 2016 | 116 | 0.030 |
Why?
|
| Genotype | 1 | 2019 | 2548 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1505 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 722 | 0.030 |
Why?
|
| South Carolina | 1 | 2011 | 10 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 2886 | 0.020 |
Why?
|
| Georgia | 1 | 2011 | 30 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 58 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 2815 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 109 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 773 | 0.020 |
Why?
|
| Veterans | 1 | 2019 | 1750 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2011 | 389 | 0.020 |
Why?
|